Vigil Neuroscience, Inc. (VIGL)
NASDAQ: VIGL · Real-Time Price · USD
1.790
0.00 (0.00%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Company Description

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States.

The company’s lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

It also developing VG-3927, an orally available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial.

It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2.

Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Vigil Neuroscience, Inc.
Vigil Neuroscience logo
Country United States
Founded 2020
IPO Date Jan 7, 2022
Industry Biotechnology
Sector Healthcare
Employees 69
CEO Ivana Magovcevic-Liebisch

Contact Details

Address:
100 Forge Road, Suite 700
Watertown, Massachusetts 02472
United States
Phone 857 254 4445
Website vigilneuro.com

Stock Details

Ticker Symbol VIGL
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $14.00
CIK Code 0001827087
CUSIP Number 92673K108
ISIN Number US92673K1088
SIC Code 2836

Key Executives

Name Position
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. President, Chief Executive Officer and Director
Jennifer Ziolkowski CPA Chief Financial Officer
Dr. Petra Kaufmann M.D., M.S. Chief Medical Officer
Sharon Morani Senior Director of Facilities and Operations
Dr. David Gray Ph.D. Chief Scientific Officer
Eric Brophy Senior Manager of Information Technology
Leah Gibson Vice President of Investor Relations and Corporate Communications
April Effort M.B.A., M.S. Vice President and Head of Corporate Development
Evan A. Thackaberry DABT, Ph.D. Senior Vice President and Head of Early Development
Christian Mirescu Ph.D. Senior Vice President and Head of Neuroimmunology

Latest SEC Filings

Date Type Title
Apr 11, 2025 424B3 Prospectus
Apr 8, 2025 EFFECT Notice of Effectiveness
Mar 31, 2025 S-3 Registration statement under Securities Act of 1933
Mar 31, 2025 ARS Filing
Mar 31, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 31, 2025 DEF 14A Other definitive proxy statements
Mar 13, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 13, 2025 10-K Annual Report
Mar 13, 2025 8-K Current Report
Feb 12, 2025 SCHEDULE 13G/A Filing